Amgen Inc (AMGN): Total Assets
$90.59B
As of 2025-12-31
$95.64B
As of 2026-06-30
+11.6%
3-year compound annual growth
+7.6%
5-year compound annual growth
+2.4%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $90.59B | -1.4% | 2026-02-13, Balance as of period end |
| 2024-12-31 | $91.84B | -5.5% | 2026-02-13, Balance as of period end |
| 2023-12-31 | $97.15B | +49.2% | 2025-02-14, Balance as of period end |
| 2022-12-31 | $65.12B | +6.5% | 2024-02-14, Balance as of period end |
| 2021-12-31 | $61.16B | -2.8% | 2023-02-09, Balance as of period end |
| 2020-12-31 | $62.95B | +5.4% | 2022-02-16, Balance as of period end |
| 2019-12-31 | $59.71B | -10.1% | 2021-02-09, Balance as of period end |
| 2018-12-31 | $66.42B | -16.9% | 2020-02-12, Balance as of period end |
| 2017-12-31 | $79.95B | +3.0% | 2019-02-13, Balance as of period end |
| 2016-12-31 | $77.63B | +8.6% | 2018-02-13, Balance as of period end |
| 2015-12-31 | $71.45B | +3.5% | 2017-02-14, Balance as of period end |
| 2014-12-31 | $69.01B | +4.4% | 2016-02-16, Balance as of period end |
| 2013-12-31 | $66.12B | +21.8% | 2015-02-19, Balance as of period end |
| 2012-12-31 | $54.30B | +11.1% | 2014-02-24, Balance as of period end |
| 2011-12-31 | $48.87B | +12.4% | 2013-02-27, Balance as of period end |
| 2010-12-31 | $43.49B | +9.7% | 2012-02-29, Balance as of period end |
| 2009-12-31 | $39.63B | +8.8% | 2011-02-25, Balance as of period end |
| 2008-12-31 | $36.43B | n/a | 2010-03-01, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Amgen Inc (AMGN) | 2025-12-31 | $90.59B | -1.4% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $59.02B | 0.0% |
| Biogen Inc. (BIIB) | 2025-12-31 | $29.44B | +5.0% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $4.63B | +24.5% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.84B | -3.5% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $6.28B | +10.4% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $12.34B | -12.8% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.53B | +22.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
Compare AMGN, GILD, BIIB, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗